Variant Creutzfeldt-Jakob disease (CJD) is a transmissible spongiform encephalopathy believed to be caused by the bovine spongiform encephalopathy agent, an abnormal isoform of the prion protein (PrP(sc)). At present there is no specific or effective treatment available for any form of CJD. Pentosan polysulphate (PPS), a large polyglycoside molecule with weak heparin-like activity, has been shown to prolong the incubation period of the intracerebral infection when administered to the cerebral ventricles in a rodent scrapie model. PPS also prevents the production of further PrP(sc) in cell culture models. These properties of PPS prompted its cerebroventricular administration in a young man with vCJD. Long-term continuous infusion of PPS at a dose of 11 microg/kg/day for 18 months did not cause drug-related side effects. Follow-up CT scans demonstrated progressive brain atrophy during PPS administration. Further basic and clinical research is needed in order to address the issue of efficacy of PPS in vCJD and in other prion diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinf.2004.07.015DOI Listing

Publication Analysis

Top Keywords

pentosan polysulphate
8
variant creutzfeldt-jakob
8
creutzfeldt-jakob disease
8
spongiform encephalopathy
8
pps
6
cerebroventricular infusion
4
infusion pentosan
4
polysulphate human
4
human variant
4
disease variant
4

Similar Publications

Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a multifactorial, chronic syndrome involving urinary frequency, urgency, and bladder discomfort. These IC/BPS symptoms can significantly impact individuals' quality of life, affecting their mental, physical, sexual, and financial well-being. Individuals sometimes rely on peer-to-peer support to understand the disease and find methods of alleviating symptoms.

View Article and Find Full Text PDF

Purpose: Although the mechanism underlying interstitial cystitis/bladder pain syndrome (IC/BPS) remains unclear, oxidative stress is suggested to be implicated in IC/BPS development. Sea buckthorn (SB; L.) contains several compounds with antioxidant properties.

View Article and Find Full Text PDF

Purpose: To evaluate prevalence and incidence rates of pigmentary maculopathy and retinopathy (PM/PR), and visual acuity (VA) changes in patients exposed to pentosan polysulfate sodium (PPS) and in patients with interstitial cystitis (IC) not exposed to PPS.

Methods: This is a retrospective cohort study (January 2015-March 2021) which included adult de-identified patients from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and Komodo Health database. Three patient cohorts were identified: two PPS-exposed patient cohorts, and Non-PPS-exposed IC patient cohort.

View Article and Find Full Text PDF

Pentosan polysulfate sodium maculopathy: Final analysis of a prospective cohort, updated review, and association with inflammatory bowel disease.

Surv Ophthalmol

December 2024

Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, CA, United States; Greater Los Angeles VA Healthcare Center (D.S.), Los Angeles, CA, USA. Electronic address:

Pentosan polysulfate sodium (PPS) maculopathy is a recently described condition of macular toxicity. We report the prevalence (15 %), the clinical characteristics, and the multimodal imaging (MMI) features of PPS maculopathy based on a final prospective analysis of a cohort of 154 subjects and highlight the association with inflammatory bowel disease (IBD). In addition, we summarize the most recent and relevant literature on PPS maculopathy.

View Article and Find Full Text PDF
Article Synopsis
  • Moderate to severe interstitial cystitis (bladder pain syndrome) currently lacks effective long-term treatments, with pentosan polysulfate having limitations and potential side effects.
  • A study involving 12 women aged 39-76 tested BPC-157, an unapproved peptide, via bladder injections to evaluate its safety and efficacy for interstitial cystitis.
  • Results showed that 10 out of 12 patients experienced complete symptom resolution after one injection, while the remaining 2 reported significant improvement, marking the first positive report on BPC-157 for this condition.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!